NanoViricides (NYSE American: NNVC), a clinical-stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, will be participating at the inaugural EF Hutton Global Conference. The two-day event is scheduled for May 10–11, 2023, in New York City. Company president Anil R. Diwan, PhD, will be presenting at the gathering; his presentation is scheduled May 10. The global conference is an elite, invitation-only event featuring key executives from some 150 public and private companies; company executives are invited to present the unique stories of their companies to institutional investors, high-net worth individuals, corporate clients and members of the press; one-on-one meetings are also available during the conference. According to the announcement, companies from an array of industries will be presenting; sectors represented include consumer and retail, energy and infrastructure, financial services, healthcare and life sciences, industrials, real estate, gaming, lodging, sustainability, technology, media and telecommunications.
To view the full press release, visit https://ibn.fm/P7jMp
About NanoViricides Inc.
NanoViricides is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Each nanoviricide drug is designed so that virus variants would be highly unlikely to escape the drug, solving a critical issue in antiviral drug development. The company’s lead drug candidate for the treatment of COVID and long COVID caused by SARS-CoV-2 coronavirus is approved to enter human clinical trials that are expected very soon. The company’s other advanced candidate is NV-HHV-1 for the treatment of shingles, which has completed IND-enabling safety/pharmacology studies. NV-CoV-2 is the company’s nanoviricide drug candidate for COVID. NV-CoV-2-R is another drug candidate for COVID that is made up of NV-CoV-2 with Remdesivir, an already approved drug, encapsulated within its polymeric micelles. Remdesivir is developed by Gilead. The company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently. The company is also developing a broad pipeline of drugs against a number of viruses, with preclinical safety and effectiveness successes achieved already in many cases. For more information about the company, please visit www.NanoViricides.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork